{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:59:17Z","timestamp":1791172757325,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.antiviral.2015.08.008","type":"journal-article","created":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T00:17:39Z","timestamp":1439338659000},"page":"69-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Immune-modulators to combat hepatitis B virus infection: From IFN-\u03b1 to novel investigational immunotherapeutic strategies"],"prefix":"10.1016","volume":"122","author":[{"given":"Nathalie","family":"Isorce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lucifora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Durantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.08.008_b0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4049\/jimmunol.177.1.315","article-title":"IFN-\u03b3 and its receptor subunit IFNGR1 are recruited to the IFN-\u03b3-activated sequence element at the promoter site of IFN-\u03b3-activated genes: evidence of transactivational activity in IFNGR1","volume":"177","author":"Ahmed","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0010","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0015","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/hep.22871","article-title":"Retreating chronic hepatitis C with daily interferon alfacon-1\/ribavirin after nonresponse to pegylated interferon\/ribavirin: DIRECT results","volume":"49","author":"Bacon","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/ni.2794","article-title":"STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling","volume":"15","author":"Begitt","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2015.08.008_b0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2015.02.026","article-title":"Interleukin 6 inhibits HBV entry through NTCP down regulation","volume":"481","author":"Bouezzedine","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0035","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/mt.2014.233","article-title":"Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination","volume":"23","author":"Brass","year":"2015","journal-title":"Mol. Ther.:J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.antiviral.2015.08.008_b0040","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/infdis\/166.5.966","article-title":"Type I interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells","volume":"166","author":"Caselmann","year":"1992","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.08.008_b0045","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/JVI.71.4.3236-3243.1997","article-title":"Interleukin-12 inhibits hepatitis B virus replication in transgenic mice","volume":"71","author":"Cavanaugh","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b9000","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.antiviral.2015.07.006","article-title":"Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure","volume":"121","author":"Chang","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.08.008_b0050","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","article-title":"HCV and HIV co-infection: mechanisms and management","volume":"11","author":"Chen","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0055","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.4049\/jimmunol.160.3.1320","article-title":"Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes","volume":"160","author":"Chow","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrgastro.2013.164","article-title":"Chronic hepatitis D at a standstill: where do we go from here?","volume":"11","author":"Ciancio","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/jgh.12671","article-title":"Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection","volume":"30","author":"Colvin","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jgh.12060","article-title":"Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI)","volume":"28","author":"Couzigou","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0080","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/embj.201488027","article-title":"Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming","volume":"33","author":"Dalod","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2015.08.008_b0085","doi-asserted-by":"crossref","first-page":"32269","DOI":"10.1074\/jbc.M404789200","article-title":"Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-lambda 1: similarities with type I interferon signaling","volume":"279","author":"Dumoutier","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.08.008_b0090","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2012.06.019","article-title":"Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option?","volume":"57","author":"Durantel","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis b virus infection","volume":"57","author":"EASL","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0100","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/emi.2014.51","article-title":"The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections","volume":"3","author":"Egli","year":"2014","journal-title":"Emerging Microbes Infect."},{"key":"10.1016\/j.antiviral.2015.08.008_b0105","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1128\/AAC.00199-06","article-title":"Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system","volume":"50","author":"Escuret","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.08.008_b0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2014.02.005","article-title":"The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?","volume":"105","author":"Feld","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.08.008_b0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11531990-000000000-00000","article-title":"Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b","volume":"70","author":"Foster","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2015.08.008_b0120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpe at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.08.008_b0130","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/JVI.75.6.2684-2691.2001","article-title":"Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein","volume":"75","author":"Gordien","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0135","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/S0168-8278(13)60380-3","article-title":"Hepatitis B core (HBC) protein is a key and very early negative regulator of the interferon response","volume":"58","author":"Gruffaz","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0140","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/JVI.68.3.1265-1270.1994","article-title":"Interleukin-2 and alpha\/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways","volume":"68","author":"Guidotti","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0145","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1073\/pnas.93.10.4589","article-title":"Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver","volume":"93","author":"Guidotti","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.antiviral.2015.08.008_b0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2015.08.008_b0155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.08.008_b0160","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1128\/JVI.76.6.2617-2621.2002","article-title":"Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice","volume":"76","author":"Guidotti","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2009.08.021","article-title":"A lymphotoxin-driven pathway to hepatocellular carcinoma","volume":"16","author":"Haybaeck","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.antiviral.2015.08.008_b0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0175","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1128\/JVI.73.1.474-481.1999","article-title":"Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice","volume":"73","author":"Heise","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0180","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.23226","article-title":"Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection","volume":"50","author":"H\u00f6sel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0185","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1128\/JVI.79.11.7269-7272.2005","article-title":"Toll-like receptor signaling inhibits hepatitis B virus replication in vivo","volume":"79","author":"Isogawa","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference I: the interferon","volume":"147","author":"Issacs","year":"1957","journal-title":"Proc. R. Soc. Lond."},{"key":"10.1016\/j.antiviral.2015.08.008_b0195","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1098\/rspb.1957.0049","article-title":"Virus interference, II: some properties of interferon","volume":"147","author":"Issacs","year":"1957","journal-title":"Proc. R. Soc. Lond."},{"key":"10.1016\/j.antiviral.2015.08.008_b9010","unstructured":"Isorce, N., Testoni, B., Locatelli, M., Luangsay, S., Fresquet, J., Zoulim, F., Durantel, D., submitted for publication. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.08.008_b0200","series-title":"Fields Virology","first-page":"189","article-title":"Innate responses to viral infections","author":"Iwasaki","year":"2013"},{"key":"10.1016\/j.antiviral.2015.08.008_b0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.08.008_b0210","doi-asserted-by":"crossref","first-page":"e1004210","DOI":"10.1371\/journal.ppat.1004210","article-title":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"10","author":"Jo","year":"2014","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.antiviral.2015.08.008_b0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.freeradbiomed.2006.10.034","article-title":"Novel role of IL-6\/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells","volume":"42","author":"Kang","year":"2007","journal-title":"Free Radical Biol. Med."},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2015.08.008_b0220","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.12400","article-title":"HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?","volume":"34","author":"Kao","year":"2014","journal-title":"Liver Int.: Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.antiviral.2015.08.008_b0225","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jmv.1890470314","article-title":"Tumor necrosis factor-alpha and interferon-gamma inhibit synergistically viral replication in hepatitis B virus-replicating cells","volume":"47","author":"Kawanishi","year":"1995","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0230","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14712598.2015.1053206","article-title":"PEGylated IFNbeta-1a in the treatment of multiple sclerosis","volume":"15","author":"Khan","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.antiviral.2015.08.008_b0235","doi-asserted-by":"crossref","first-page":"10702","DOI":"10.1128\/JVI.76.21.10702-10707.2002","article-title":"Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice","volume":"76","author":"Kimura","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0240","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00430-014-0377-7","article-title":"Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?","volume":"204","author":"Koh","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0245","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0250","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.08.008_b0255","series-title":"Fundamental Immunology","first-page":"601","article-title":"Type I cytokines and interferons, an their receptors","author":"Leonard","year":"2013"},{"key":"10.1016\/j.antiviral.2015.08.008_b0260","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.antiviral.2015.08.008_b0265","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.antiviral.2015.08.008_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.06.022","article-title":"Expression and functionality of toll- and RIG-like receptors in HepaRG Cells","author":"Luangsay","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0275","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.08.008_b0280","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.24189","article-title":"Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo","volume":"53","author":"Makowska","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0285","doi-asserted-by":"crossref","first-page":"e1003494","DOI":"10.1371\/journal.ppat.1003494","article-title":"Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein","volume":"9","author":"Mao","year":"2013","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.antiviral.2015.08.008_b0290","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.08.008_b0295","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.08.008_b0300","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1128\/JVI.74.5.2255-2264.2000","article-title":"Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines","volume":"74","author":"McClary","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mcna.2013.08.004","article-title":"Chronic hepatitis B virus infection","volume":"98","author":"McMahon","year":"2014","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.antiviral.2015.08.008_b0310","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0315","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","author":"Micco","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0320","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jhep.2014.07.022","article-title":"A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection","volume":"61","author":"Muir","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0325","series-title":"Fundamental Immunology","first-page":"681","article-title":"Chemokines","author":"Murphy","year":"2013"},{"key":"10.1016\/j.antiviral.2015.08.008_b0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059611","article-title":"Targeted induction of interferon-\u03bb in humanized chimeric mouse liver abrogates hepatotropic virus infection","volume":"8","author":"Nakagawa","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.08.008_b0335","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/j.gastro.2010.06.062","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3","volume":"139","author":"Nelson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0340","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1128\/JVI.02510-06","article-title":"Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G","volume":"81","author":"Nguyen","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0345","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ng.2955","article-title":"Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer","volume":"46","author":"Nik-Zainal","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2015.08.008_b0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jir.1992.12.55","article-title":"A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities","volume":"12","author":"Ozes","year":"1992","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.antiviral.2015.08.008_b0355","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.virol.2010.02.022","article-title":"Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities","volume":"401","author":"Pagliaccetti","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0360","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1084\/jem.192.4.529","article-title":"Host-virus interactions during malaria infection in hepatitis B virus transgenic mice","volume":"192","author":"Pasquetto","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2015.08.008_b0365","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1128\/JVI.76.11.5646-5653.2002","article-title":"Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures","volume":"76","author":"Pasquetto","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0370","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0168-8278(99)80279-7","article-title":"Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells","volume":"31","author":"Rang","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0375","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0380","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-immunol-031210-101345","article-title":"Plasmacytoid dendritic cells: recent progress and open questions","volume":"29","author":"Reizis","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0385","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","article-title":"Lambda interferon inhibits hepatitis B and C virus replication","volume":"79","author":"Robek","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0390","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3389\/fimmu.2013.00498","article-title":"The significance of interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis","volume":"4","author":"Roff","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0395","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/jvh.12023","article-title":"In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes","volume":"20","author":"Saade","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.08.008_b0400","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0405","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2015.08.008_b0410","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.008_b0415","series-title":"Field\u2019s Virology","first-page":"2185","article-title":"Hepadnaviruses","author":"Seeger","year":"2015"},{"key":"10.1016\/j.antiviral.2015.08.008_b0420","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/imm.12362","article-title":"Clinical implications of interferon-\u03b3 genetic and epigenetic variants","volume":"143","author":"Smith","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0425","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coi.2015.03.002","article-title":"New insights into type I interferon and the immunopathogenesis of persistent viral infections","volume":"34","author":"Snell","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0430","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nbt1364","article-title":"Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C","volume":"25","author":"Subramanian","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0435","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0440","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/jir.2014.0138","article-title":"Development of a hyperglycosylated IFN Alfacon-1 (CIFN): toward bimonthly or monthly dosing for antiviral therapies","volume":"35","author":"Taylor","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.antiviral.2015.08.008_b0445","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?","volume":"58","author":"Thimme","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0450","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.3748\/wjg.v20.i20.6226","article-title":"Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection","volume":"20","author":"Tun\u00e7bilek","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0455","doi-asserted-by":"crossref","first-page":"e39179","DOI":"10.1371\/journal.pone.0039179","article-title":"PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model","volume":"7","author":"Tzeng","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.08.008_b0460","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1172\/JCI75254","article-title":"Evasion of inflammasome activation by microbial pathogens","volume":"125","author":"Ulland","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2015.08.008_b0465","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcdb.2014.05.016","article-title":"BDCA3+CLEC9A+ human dendritic cell function and development","volume":"41","author":"van der Aa","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0470","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1007\/s00018-008-8064-8","article-title":"TLR-4, IL-1R and TNF-R signaling to NF-\u03baB: variations on a common theme","volume":"65","author":"Verstrepen","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.antiviral.2015.08.008_b0475","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/hep.21482","article-title":"Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein","volume":"45","author":"Visvanathan","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0480","doi-asserted-by":"crossref","first-page":"31715","DOI":"10.1074\/jbc.M113.501122","article-title":"Interleukin-1 and tumor necrosis factor-\u03b1 trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)","volume":"288","author":"Watashi","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.08.008_b0485","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.08.008_b0490","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1542-3565(05)00404-0","article-title":"Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study","volume":"3","author":"Weng","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0495","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1128\/JVI.74.9.4165-4173.2000","article-title":"Intrahepatic induction of alpha\/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice","volume":"74","author":"Wieland","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0500","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.08.008_b0505","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.1254083","article-title":"Virology. Response to Comment on \u201cSpecific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA\u201d","volume":"344","author":"Xia","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.08.008_b0510","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2893.2012.01589.x","article-title":"A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy","volume":"19","author":"Yang","year":"2012","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.08.008_b0515","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.antiviral.2015.08.008_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(13)60337-2","article-title":"HBV inhibits the aim-2 inflammasome in human kupffer cells","volume":"58","author":"Zannetti","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0525","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1","volume":"139","author":"Zeuzem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.08.008_b0530","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2012.05.004","article-title":"Role of Toll-like receptor 2 in the immune response against hepadnaviral infection","volume":"57","author":"Zhang","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0535","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1743-422X-6-99","article-title":"Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial","volume":"6","author":"Zheng","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2015.08.008_b0540","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.008_b0545","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T22:53:07Z","timestamp":1691880787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":111,"alternative-id":["S0166354215001941"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.08.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-modulators to combat hepatitis B virus infection: From IFN-\u03b1 to novel investigational immunotherapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}